leadf
logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience files application with senior US stock exchange to request an uplisting of its common stock

The group believes a successful uplisting should provide significant benefits to its shareholders that include increased liquidity, a much larger audience of institutional funds, improved visibility, and improved access to capital

Share uplisting
Such benefits could prove to be transformative for Lexaria in advancing its drug delivery technology, the group added

Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX), a global innovator in drug delivery platforms, said it has filed an application with a senior stock exchange in the United States to request an uplisting of the company's common stock.

In a statement, Lexaria said it believes it will be positioned to meet the required listing qualifications for the senior exchange and that a successful uplisting to a senior US stock exchange should provide significant benefits to its shareholders that include increased liquidity, a much larger audience of institutional funds, improved visibility, and improved access to capital.

READ: Lexaria Bioscience finalizes first phase of research program on DehydraTECH oral nicotine formulation with Altria Ventures

It noted that as the company increases its focus on pharmaceutical and oral nicotine applications of its patented technology, such benefits could prove to be transformative for Lexaria in advancing its drug delivery technology.

Chris Bunka, the company’s chief executive officer commented: "Lexaria has achieved some impressive milestones in recent years through the discovery and development of our DehydraTECH technology platform.”

"In addition, we have significantly expanded our shareholder base and during our recent annual general meeting, have received overwhelming shareholder approval to advance the Company to a senior US stock exchange, in hopes of delivering increased investor recognition for our Company as well as value to our shareholders," he added.

The group said review of the company's application is underway and may require many weeks or months to draw to a conclusion and, while the firm believes it will be able to comply with all the necessary regulatory requirements, no assurances can be made that the application will be successful.

Lexaria’s proprietary drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing.

The company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules.

Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. It operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

Quick facts: Lexaria Bioscience Corp.

Price: 0.35 CAD

CSE:LXX
Market: CSE
Market Cap: $31.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Lexaria Bioscience signs R&D agreement with British American Tobacco

Lexaria Bioscience (CSE: LXRP-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to share news the company has signed a deal with British American Tobacco Limited. That company has products sold in over 11 million locations across more than 180 countries. Bunka telling...

2 weeks, 3 days ago

2 min read